STOCKS TELEGRAPH

Tag: NKTR Stock Price

  • Nektar Therapeutics (NKTR) Stock Surges In Extended Session

    Nektar Therapeutics (NKTR) Stock Surges In Extended Session

    Investor anticipation ahead of fresh trial results propelled Nektar Therapeutics (NASDAQ: NKTR) to notable market momentum on Monday. Following a 12.10% rise during the regular session, when the stock ended at $9.54, shares jumped 35.32% in after-hours trading to close at $12.91. The rise preceded a webcast and investor call to reveal top-line findings from a worldwide Phase 2b study.

    Future Data Presentation Encourages Market Hope

    Initial findings from the 16-week induction phase of the current REZOLVE-AD study will be the focus of the investor call and live webcast. In this study, individuals with moderate-to-severe atopic dermatitis are evaluated for the effectiveness of Nektar Therapeutics’ experimental treatment, rezpegaldesleukin, a regulatory T-cell (Treg) stimulator. Key findings will be detailed in a morning news release that will accompany the presentation. A webcast replay will be accessible on the company’s investor relations website for at least 30 days after the event.

    Clinical Program Development Across Indications

    With 396 patients enrolled in the REZOLVE-AD study, Nektar Therapeutics met its enrollment goal in January. The following month, NKTR also completed the enrollment of 84 patients with severe-to-very severe alopecia areata in the Phase 2b study, REZOLVE-AA.

    Additionally, Nektar Therapeutics conducted a Phase 2 trial evaluating rezpegaldesleukin in around 70 people who had just been diagnosed with type 1 diabetes in collaboration with a leading diabetes research consortium TrialNet.

    Regulatory Recognition and Global Scientific Opinions

    Rezpegaldesleukin’s promise as a medicine was further supported in February when the U.S. Food and Drug Administration (FDA) granted it Fast Track designation. Nektar Therapeutics’ collaborative work was showcased at the 30th Annual Congress of the European Hematological Association (EHA) in Milan.

    The presentation was developed in partnership with the Fred Hutchinson Cancer Center that highlighted the positive results that NKTR-255 and lisocabtagene maraleucel produced for patients with relapsed or refractory large B-cell lymphoma.

    Because of its strong clinical pipeline and regulatory achievements, continue to bolster investor confidence, Nektar Therapeutics (NKTR) is positioned as a leading competitor in immune-modulating medications.

  • Nektar Therapeutics (NKTR) Stock on a Rise in Aftermarket, Here’s Why

    Nektar Therapeutics (NKTR) Stock on a Rise in Aftermarket, Here’s Why

    Nektar Therapeutics (NKTR), a biopharmaceutical company, has surged 10.34% in aftermarket trading session. Consequently, NKTR stock is trading at $11.95 at the time of the writing. The surge could be attributed to the announcement that the company would join the S&P midcap 400. On Friday, NKTR closed the day at $10.83 after declining 5.08% during regular trading hours.

    Why NKTR Surging?

    On Friday, it was announced that there would be numerous index changes in S&P Dow Jones Indices, including S&P 500, S&P MidCap 400, and S&P SmallCap 600. The changes were to be effective before the opening of trading on 20th December 2021. That in turn would coincide with the quarterly balances. NKTR, earlier being part of S&P MidCap 400, will move to S&P SmallCap 600.

    Q3 2021 Operational Results

    On 4th November, NKTR released the operational results for the third quarter of the fiscal year 2021. The quarter ended on 30th September. The company generated total revenue of $24.92 million during the quarter against $30 million for the same period of 2020. The total operating expenses bore by the company during the three months were $138.5 million against $133 million for the same period of 2020. The net loss suffered by the company during the quarter was $129.7 million (or $0.70 per basic and diluted share) against $108.5 million (or $0.61 per basic and diluted share) for the same quarter of fiscal 2021.

    Executive Commentary

    Howard W. Robin, President and CEO of NKTR, while commenting on the results said that the company has made significant progress across its portfolio during this past quarter. He hoped that based on the reliance upon innovation, as evident in the policies of the company, it would be able to bring further improvements in its performance during the upcoming quarter.

    Future Outlook for NKTR

    During the last month, NKTR stock has declined more than 30%. However, the analysts believe that the stock is in a good shape to achieve success in the near future. Hence, potential investors should keep a close eye on the performance of NKTR stock.